D001378Chemicals & DrugsD04.210.500.925.100350.996866Azasteroidsprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson0.4867970.05376853research area of0.4446260.08751626subject area for2156887Gormley GJ, Stoner E, Rittmaster RS, Gregg H, Thompson DL, Lasseter KC, Vlasses PH, Stein EAThe Journal of clinical endocrinology and metabolismEffects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab. 1990 Apr; 70(4):1136-41.J Clin Endocrinol Metab1990-04-01T00:00:001990Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.20206978Chung DE, Te AE, Staskin DR, Kaplan SAUrologyEfficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology. 2010 May; 75(5):1144-8.Urology2010-03-05T00:00:002010Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams.22818135Kaplan SA, Lee RK, Chung DE, Te AE, Scherr DS, Tewari A, Vaughan EDThe Journal of urologyProstate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5a-reductase inhibitors markedly enhances the detection rate of prostate cancer. J Urol. 2012 Sep; 188(3):757-61.J Urol2012-07-19T00:00:002012Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5a-reductase inhibitors markedly enhances the detection rate of prostate cancer.MedicineSurgeryUniversity of ChicagoScott E.EggenerScott E. Eggener41.78927490000000-87.601250000000001156Eggener, Scott E.ProfessorDoreenChungDoreen Chung41.78927490000000-87.601250000000001295Chung, DoreenClinical AssociateDanielShevrinDaniel H. Shevrin41.78927490000000-87.60125000000000445Shevrin, DanielCLINICAL ASSOCIATE PROFESSORtrue1CLINICAL ASSOCIATE PROFESSORCLINICAL ASSOCIATE PROFESSORtrue1Clinical AssociateClinical Associatetrue1ProfessorProfessor20564326Gupta S, Wang Y, Ramos-Garcia R, Shevrin D, Nelson JB, Wang ZThe ProstateInhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. Prostate. 2010 Oct 01; 70(14):1575-85.Prostate2010-10-01T00:00:002010Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.Surgery-Urology23671262Masoodi KZ, Ramos Garcia R, Pascal LE, Wang Y, Ma HM, O'Malley K, Eisermann K, Shevrin DH, Nguyen HM, Vessella RL, Nelson JB, Parikh RA, Wang ZEndocrinology5a-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. Endocrinology. 2013 Jul; 154(7):2296-307.Endocrinology2013-05-13T00:00:0020135a-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.